MorphoSys AG operates primarily in the biotechnology and pharmaceutical industries.

The main competitors of MorphoSys AG in the market include biotechnology companies such as Roche Holding AG, Amgen Inc., and Gilead Sciences Inc.

MorphoSys AG is a renowned biopharmaceutical company headquartered in Germany. It was founded in 1992 and has since established itself as a global leader in the field of therapeutic antibodies. The company specializes in developing innovative drugs to address unmet medical needs. MorphoSys AG utilizes its unique technology, known as HuCAL (Human Combinatorial Antibody Library), which enables the efficient discovery and optimization of fully human antibodies. With a focus on oncology and autoimmune disorders, MorphoSys AG has successfully collaborated with numerous pharmaceutical partners to bring novel treatments to patients worldwide. The company's commitment to scientific excellence and dedication to improving human health has propelled its growth and reputation in the industry.

Some significant milestones achieved by MorphoSys AG include the successful development and approval of several innovative antibodies and their subsequent commercialization. The company's antibody MorphoSys-derived was the first fully human therapeutic antibody to receive marketing approval in the European Union. MorphoSys AG has also entered into strategic partnerships with various pharmaceutical companies, expanding its pipeline and driving strong financial growth. Furthermore, the company received FDA approval for its antibody, marketed as Monjuvi, for the treatment of certain lymphoma cancers. These milestones demonstrate MorphoSys AG's dedication to advancing novel therapies and its position as a leader in the field of antibody-based therapeutic development.

MorphoSys AG is primarily present in various countries and regions across the globe. The company has a significant presence in Germany, where its headquarters are located. Additionally, MorphoSys AG has established a strong presence in the United States, with offices in the state of Massachusetts. Furthermore, the company has expanded its reach to other key markets, including the United Kingdom, Switzerland, Austria, and other European countries. With its global footprint, MorphoSys AG has successfully penetrated multiple international markets, solidifying its presence in the biotechnology and pharmaceutical industries.

MorphoSys AG represents values of innovation, collaboration, and scientific advancement in the biotechnology industry. As a leading company, MorphoSys focuses on developing therapeutic antibodies to address unmet medical needs. With their corporate philosophy centered around cutting-edge science and a patient-centric approach, MorphoSys aims to improve the lives of patients worldwide. By employing their unique proprietary technology, they continually strive to advance the field of antibody research and development. Through their commitment to excellence and passion for transforming healthcare, MorphoSys AG stands as a progressive and influential player within the biotech sector.

12 analysts currently rate the MorphoSys stock: 5 recommend buying, 7 holding and 0 selling. For 2026, analysts expect MorphoSys to generate revenue of 449,11 M EUR and earnings per share of −1,03 EUR.

MorphoSys Analyytikkojen kursstavoitteet 2026

The MorphoSys share (MOR.DE) is listed on 13 stock exchanges, including: NASDAQ (MPSYF), XETRA (MOR.DE), Frankfurt (MOR.F), München (MOR.MU), Stuttgart (MOR.SG), Düsseldorf (MOR.DU), Berlin (MOR.BE), Hamburg (MOR.HM).

MorphoSys AG is a biopharmaceutical company headquartered in Planegg near Munich. It was founded in 1992 and has been listed on the stock exchange since 1999. MorphoSys's business model is focused on developing and bringing to market new and innovative therapies for cancer and other serious diseases. MorphoSys focuses on the discovery, development, and commercialization of therapeutic antibodies - proteins specifically targeting certain structures in the body. The company's main products are the antibody therapeutics Tremfya® and Monjuvi®, used for the treatment of skin and blood cancers. Some of the areas in which MorphoSys operates include antibody research and conducting clinical studies, licensing technologies and know-how, selling licenses and patent rights, as well as collaborating with other pharmaceutical and biotech companies to develop new therapies. MorphoSys has a broad portfolio of antibodies and technologies based on its in-house HuCAL® antibody technology. This technology allows for the production of antibodies against almost any desired target structure in the body. MorphoSys also works with partners to utilize this technology in the development of new therapies in multiple areas, including oncology (cancer treatment), inflammatory and infectious diseases, and autoimmune diseases. MorphoSys also has its own clinical development department, which focuses on conducting clinical studies to evaluate the safety and efficacy of antibody therapeutics. The company has several clinical development programs in oncology and other therapeutic areas, and works closely with other partners to develop and bring new therapies to market. MorphoSys also offers various services related to the HuCAL® technology, including the creation of antibody libraries, on-demand antibody production, and antibody optimization for specific applications. The company also has a platform for antibody engineering technology called Ylanthia®, which allows for the development of specific antibodies for clients. Overall, MorphoSys's business model is based on the research, development, and commercialization of innovative antibody-based therapies. The company's divisions include research, clinical development, marketing, and technology licensing. The company is well positioned to unlock the potential of new therapies and grow in the biopharmaceutical products market.

odotettu liikevaihto MorphoSys on 449,11 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto MorphoSys on −40,89 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

P/E-suhdetta ei voida laskea MorphoSys:lle tällä hetkellä.

P/S-suhdetta ei voida laskea MorphoSys:lle tällä hetkellä.

MorphoSys:n Eulpool-laatuscore on 2/10.

MorphoSys:n ISIN on DE0006632003. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

MorphoSys:n WKN on 663200. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

MorphoSys:n ticker on MOR.DE. Tämä pörssinoteeraus käytetään MorphoSys-osakkeiden kauppaan pörssissä.

MorphoSys kuuluu sektoriin 'Terveydenhuolto'.

MorphoSys:n osingot jaetaan valuutassa EUR.